$2.85
0.3%
Price vs. AI Score (Last 150 days)
Data gathered: December 9
Data gathered: December 9
Data Bits
| Data Bits | Value / Change | Benchmark |
|---|---|---|
| Job Posts | N/A | N/A |
| Sentiment | N/A | N/A |
| Webpage traffic | N/A | N/A |
| Employee Rating | N/A | N/A |
| Google Trends | N/A | N/A |
| Linkedin Employees | N/A | N/A |
| Lobbying Cost | $ N/A | N/A |
| Patents | N/A | N/A |
| 4chan Mentions | N/A | N/A |
| Stocktwits Mentions | N/A | N/A |
| Stocktwits Subscribers | N/A | N/A |
| Twitter Followers | N/A | N/A |
| Youtube Subscribers | N/A | N/A |
| Instagram Followers | N/A | N/A |
| News Mentions | N/A | N/A |
| Reddit Mentions | N/A | N/A |
| Business outlook | N/A | N/A |
In the news
Morgan Stanley Upgrades Bluebird bio (BLUE)December 8 - Fintel |
|
 |
Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is NonplussedDecember 8 - SeekingAlpha |
 |
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive EventsDecember 8 - Yahoo |
 |
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive EventsDecember 8 - Yahoo |
 |
FDA Approves World’s First Crispr Gene-Editing Drug for Sickle-Cell DiseaseDecember 8 - Yahoo |
Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell TreatmentDecember 7 - Finnhub |
|
About Bluebird bio
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases.
| Price | $2.85 |
| Target Price | Sign up |
| Market Cap | $526M |
| Dividend Yield | 0 |
| Industry | Biotechnology |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q3 '23 | 12M | 11M | 1.4M | -72M | -84M |
| Q2 '23 | 6.9M | 9.6M | -2.7M | -73M | -84M |
| Q1 '23 | 2.4M | 3.4M | -1,000,000 | 21M | 9.5M |
| Q4 '22 | 62,000 | 29M | -32M | 32M | 27M |
| Q3 '22 | 71,000 | 0 | 71,000 | -77M | -83M |
Insider Transactions
| Krawtschuk Christopher filed to sell 45,474 shares at $4.5. December 8 '23 |
| Obenshain Andrew filed to sell 291,134 shares at $3.2. November 3 '23 |
| Colvin Richard A filed to sell 125,735 shares at $3. November 3 '23 |
| Klima Thomas J filed to sell 132,127 shares at $3.8. September 6 '23 |
| Obenshain Andrew filed to sell 291,941 shares at $3.5. August 10 '23 |
Read more about Bluebird bio and their earnings, price prediction, job posts, sentiment, webpage traffic, employee rating, google trends, linkedin employees, lobbying cost, patents, 4chan mentions, stocktwits mentions, stocktwits subscribers, twitter followers, youtube subscribers, instagram followers, news mentions, reddit mentions, business outlook.